Retraction and republication—Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Author:
- The Editors of The Lancet Respiratory MedicineTMThe Editors of The Lancet Respiratory Medicine
- 27 March 2024
- journal article
- retraction
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 12 (4) , 262-263
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- MERIT reloaded—what has changed in CTEPH management since 2017?The Lancet Respiratory Medicine, 2024
- Macitentan for treatment of CTEPH: why MERIT merits attentionThe Lancet Respiratory Medicine, 2017
- RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled studyThe Lancet Respiratory Medicine, 2017